GlassScriptPhysician profile
Jonathan N Zinberg
NPI 1003898602
$7,526.91
in general payments reported to CMS, 2019-2025
33 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $306 · 2021: $538 · 2022: $1,350 · 2023: $1,257 · 2024: $1,308 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Education: $89.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.09 |
| Education | $89.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,860.03 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $884.10 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $673.09 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $558.19 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $496.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $321.55 | 2022-2025 | Dupixent |
| Celgene Corporation | $313.04 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $281.46 | 2020-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $218.78 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $179.36 | 2019-2024 | Suflave, Sutab |
| Lilly USA, LLC | $171.99 | 2023-2025 | Omvoh, Zepbound |
| Steris Corporation | $148.46 | 2024 | |
| Merck Sharp & Dohme LLC | $145.17 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $138.57 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $134.12 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $122.17 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $109.60 | 2022-2024 | |
| Madrigal Pharmaceuticals | $85.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $84.81 | 2020-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $83.23 | 2022-2023 | Ocaliva |
| Celltrion USA INC. | $79.86 | 2024 | Zymfentra |
| Allergan, INC. | $72.45 | 2019 | |
| Intra-Sana Laboratories | $49.67 | 2022-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Nestle Healthcare Nutrition INC. | $46.67 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $43.63 | 2025 | Iqirvo |
| Concordia Pharmaceuticals INC. | $39.48 | 2019 | |
| Qol Medical, LLC | $38.22 | 2020-2023 | Sucraid |
| Evoke Pharma, INC. | $34.47 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $32.98 | 2025 | Vowst |
| Anx Robotica Corp | $27.50 | 2025 | |
| Novo Nordisk INC | $23.30 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $19.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Zinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.